Krystal Biotech, Inc. Analyst EPS Estimates
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 2 | $0.27 | $0.27 | $0.27 |
Q2 2024 | 2 | $0.73 | $0.73 | $0.73 |
Q3 2024 | 1 | $0.98 | $1.01 | $0.99 |
Q4 2024 | 3 | $0.91 | $1.71 | $1.18 |
Q1 2025 | 2 | $0.88 | $1.25 | $1.07 |
Q2 2025 | 1 | $1.12 | $1.26 | $1.21 |
Q3 2025 | 1 | $1.18 | $1.33 | $1.27 |
Q4 2025 | 1 | $1.28 | $1.44 | $1.38 |
Q1 2026 | 1 | $0.79 | $0.88 | $0.84 |
Q2 2026 | 1 | $1.25 | $1.40 | $1.34 |
Q3 2026 | 1 | $1.31 | $1.47 | $1.40 |
Q4 2026 | 1 | $1.23 | $1.38 | $1.32 |
Q1 2027 | 1 | $1.56 | $1.75 | $1.67 |
Q2 2027 | 1 | $1.58 | $1.77 | $1.69 |
Q3 2027 | 1 | $2.09 | $2.34 | $2.24 |
Q4 2027 | 1 | $2.60 | $2.91 | $2.79 |
Krystal Biotech, Inc. Earnings Date And Information
Krystal Biotech, Inc. last posted its earnings results on Monday, November 4th, 2024. The company reported $0.91 earnings per share for the quarter, topping analysts' consensus estimates of $0.9 by $0.01. The company had revenue of 83.84 M for the quarter and had revenue of 50.70 M for the year. Krystal Biotech, Inc. has generated $0 earnings per share over the last year ($0.39 diluted earnings per share) and currently has a price-to-earnings ratio of 104.4. Krystal Biotech, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 24th, 2025 based on prior year's report dates.
Krystal Biotech, Inc. Earnings History by Quarter
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/04/2024 | Q2 2024 | $0.90 | $0.95 | 0.05 | $82.94 M | $83.84 M |
08/05/2024 | Q1 2024 | $0.50 | $0.54 | 0.04 | $65.27 M | $70.28 M |
05/06/2024 | Q4 2023 | $0.15 | $0.03 | -0.12 | $45.25 M | |
02/26/2024 | Q3 2023 | -$0.38 | $0.31 | 0.69 | $42.14 M | |
11/06/2023 | Q2 2023 | -$1.10 | $2.88 | 3.98 | $6.29 M | $8.56 M |
08/07/2023 | Q1 2023 | -$0.42 | -$1.25 | -0.83 | $0 | |
05/08/2023 | Q4 2022 | -$1.41 | -$1.76 | -0.35 | $0 | |
02/27/2023 | Q3 2022 | -$1.39 | -$1.25 | 0.14 | $0 | |
11/07/2022 | Q2 2022 | -$1.23 | -$1.17 | 0.06 | $0 | |
08/08/2022 | Q1 2022 | -$1.08 | -$1.10 | -0.02 | $0 | |
05/09/2022 | Q4 2021 | -$0.96 | -$1.99 | -1.03 | $0 | |
02/28/2022 | Q3 2021 | -$0.76 | -$0.95 | -0.19 | $0 | |
11/08/2021 | Q2 2021 | -$0.75 | -$0.70 | 0.05 | $0 | |
08/09/2021 | Q1 2021 | -$0.74 | -$0.74 | 0 | $0 | |
05/10/2021 | Q4 2020 | -$0.55 | -$0.74 | -0.19 | $0 | |
03/01/2021 | Q3 2020 | -$0.55 | -$0.53 | 0.02 | $0 | |
11/06/2020 | Q2 2020 | -$0.44 | -$0.49 | -0.05 | $0 | |
08/07/2020 | Q1 2020 | -$0.37 | $0 | |||
05/01/2020 | Q4 2019 | -$0.42 | -$0.31 | 0.11 | $0 | |
03/10/2020 | Q3 2019 | -$0.33 | -$0.31 | 0.02 | $0 |
Krystal Biotech, Inc. Earnings: Frequently Asked Questions
-
When is Krystal Biotech, Inc.'s earnings date?
Krystal Biotech, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 24th, 2025 based off last year's report dates.
-
Did Krystal Biotech, Inc. beat their earnings estimates last quarter?
In the previous quarter, Krystal Biotech, Inc. (:KRYS) reported $0.91 earnings per share (EPS) to beat the analysts' consensus estimate of $0.9 by $0.01.
-
How can I listen to Krystal Biotech, Inc.'s earnings conference call?
The conference call for Krystal Biotech, Inc.'s latest earnings report can be listened to online.
-
How can I read Krystal Biotech, Inc.'s conference call transcript?
The conference call transcript for Krystal Biotech, Inc.'s latest earnings report can be read online.
-
How much revenue does Krystal Biotech, Inc. generate each year?
Krystal Biotech, Inc. (:KRYS) has a recorded annual revenue of $50.70 M.
-
How much profit does Krystal Biotech, Inc. generate each year?
Krystal Biotech, Inc. (:KRYS) has a recorded net income of $50.70 M. Krystal Biotech, Inc. has generated $0.4 earnings per share over the last four quarters.
-
What is Krystal Biotech, Inc.'s price-to-earnings ratio?
Krystal Biotech, Inc. (:KRYS) has a price-to-earnings ratio of 104.4 and price/earnings-to-growth ratio is -2.03.